The frontal lobe syndrome

Krudop, W.A.

2016

document version
Publisher's PDF, also known as Version of record

Link to publication in VU Research Portal

citation for published version (APA)
Krudop, W. A. (2016). *The frontal lobe syndrome: A neuropsychiatric challenge*.

Chapter 4

SCHIZOPHRENIA AS A MIMIC OF BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA

Cora J Kerssens, Welmoed A Krudop, Niels D Prins, Bart NM van Berckel, Annemieke Rozemuller, William W Seeley, Philip Scheltens, Max L Stek, Yolande AL Pijnenburg

ABSTRACT

Recently the diagnostic criteria for the behavioral variant of frontotemporal dementia were revised. Although these criteria offer a relatively high sensitivity, their specificity is yet unknown. We describe a 54-year-old woman fulfilling criteria for both late-onset schizophrenia and probable behavioral variant frontotemporal dementia. Following an initial presentation with psychosis, she developed progressive apathy, compulsiveness and executive dysfunction. Moreover, bilateral frontotemporal hypometabolism was seen on [^{18}F]FDG-positron emission tomography. A post-mortem diagnosis of schizophrenia was established, given the clinical picture combined with the pathological exclusion of a neurodegenerative cause. Our case suggests that patients with other brain disorders may meet the current diagnostic criteria for probable frontotemporal dementia. Further clinicopathological validation of these criteria is needed to determine their exact specificity.

INTRODUCTION

The behavioral variant of frontotemporal dementia (bvFTD) is a neurodegenerative disorder primarily affecting the frontal and/or temporal lobes [1]. The bvFTD syndrome is characterized by deterioration of social-emotional function, followed by progressive changes in behavior and personality and disorders of executive functioning, memory and language [2].

The clinical diagnosis of bvFTD is based on consensus diagnostic criteria. The formerly used international diagnostic criteria by Neary et al have recently been revised by the International bvFTD Criteria Consortium (FTDC) [3;4]. One of the considerations inciting this revision was the difficulty in the application of 5 obligatory core behavioral criteria, which were subject to multiple interpretations. Moreover, a variety of psychiatric disorders could easily be misdiagnosed as bvFTD, based on the presence of overlapping symptoms [5].

The FTDC introduced a level of certainty and a more flexible clinical rating system within the new diagnostic criteria. According to these criteria, *probable* bvFTD requires at least three out of six symptom clusters in the presence of both functional decline and characteristic neuroimaging abnormalities. A specific pattern of mainly fronto-temporal atrophy can be found on structural magnetic resonance imaging (MRI) [2]. [18F]FDG-Positron Emission Tomography ([18F]FDG-PET) has an added value over MRI alone in identifying disease specific neuronal correlates in bvFTD [6]. Although it has been confirmed that the new criteria offer a reasonable sensitivity of 76% for probable bvFTD, their specificity is still unknown. The distinction of bvFTD from psychiatric disorders is essential, especially since bvFTD is progressive and will eventually lead to death whereas most psychiatric disorders are potentially treatable.

In this case report we describe the diagnostic dilemma that may occur when bvFTD symptom clusters occur in late-onset psychiatric disorder and are accompanied by functional decline and neuroimaging abnormalities.

CASE

A 54-year-old woman was admitted to a geriatric psychiatry hospital with newly developed psychotic symptoms, consisting of both delusions and auditory hallucinations. According to the patient, strangers entered her house to steal her letters and passing black cars were out to kidnap her. She also heard accusing male voices when she was alone in her house. Twenty years before she had successfully received behavioral therapy for an anxiety disorder. Nine years prior to admission, she had had complaints of tiredness and lack of energy that had been interpreted as work related stress. Although previously well-functioning in her job as an executive secretary, thereafter she never returned to her old level of functioning.

Her somatic history revealed hypertension and cardiac arrhythmia with an implantable cardioverter defibrillator. Her brother had been diagnosed with schizophrenia and committed suicide at the age of 45 years. The family history was negative for dementia. Although she had always preferred an isolated life style, she had two close friends. Her 15-year lasting relationship ended 5 years prior to presentation.

Apart from the psychotic features, psychiatric examination revealed a paucity of spontaneous speech without any apparent cognitive or motor symptoms.

She was diagnosed by the old-age psychiatrist with late-onset schizophrenia, meeting the DSM-IV criteria of (late-onset) schizophrenia [7]. The persecutory and reference delusions and hallucinations disappeared with 10 mg Olanzapine daily within three months. The remaining lack of initiative and paucity of speech were considered so called "negative" symptoms of schizophrenia. After discharge, however the clinical picture deteriorated rapidly. She did not cook for herself, forgot her appointments with her therapist and stayed in bed all day. Moreover, she developed strikingly compulsive behavior, consisting of a strong attachment to daily schedules and preoccupation with the same subjects. Additionally she was not able to organize complex tasks, such as finances and household tasks. Because of this unexpected behavioral and cognitive decline, within three months the patient was readmitted for further observation and neurological consultation.

Formal neurological examination revealed no abnormalities. On observation, she was rigid in her day program and fixated on her medication. She became very agitated when challenged to deviation. She had some awareness of her disease, but her disease-insight was reduced. Spatial orientation and memory were not disturbed. On the Frontal Assessment Battery she scored 15 out of 18. Her Mini-Mental State Examination was 29 out of 30. A neuropsychological examination confirmed the executive dysfunction (reduced planning and flexibility, impulsivity) and demonstrated minor memory impairments, with decreased learning and information retention abilities.

Because of the striking apathy, compulsiveness and executive dysfunction in the presence of functional decline over a relatively short time, a diagnosis of bvFTD was now considered. MRI of the brain was within normal limits, particularly lacking frontotemporal atrophy (Figure 1a and 1b). Subsequently, [^{18}F]FDG-PET was performed and showed bilateral frontal and anterior temporal hypometabolism on visual rating. A voxel-by-voxel analysis using a validated discrimination tool comparing the regions to a mask based on age and gender matched controls showed hypometabolism in frontal, temporal and cingulate regions (figure 1c) [8].

Analysis of the cerebrospinal fluid showed slightly decreased amyloid-beta(1-42) levels (471 ng/L) in combination with a normal total tau level (59 ng/L) and a normal phosphorylated tau level (<16 ng/L). A decreased CSF amyloid-beta(1-42) level combined with increased total tau and phosphorylated tau levels fit an Alzheimer's disease (AD) profile. However, the

clinical relevance of an isolated decreased amyloid-beta(1-42) level is unclear, especially at an older age [9-11]. In order to obtain more certainty, a ^{11}C-Pittsburgh compound B-PET scan was performed, which did not show any amyloid deposition. So even though a frontal variant of AD should be considered in behavioral changes at an older age, this seemed not to be the case in this patient [12]. Based on these findings a diagnosis of probable bvFTD was deemed plausible, although some diagnostic doubt remained since she kept some awareness of her illness and was remarkably empathic towards personnel and other patients. Because of serious self neglect the patient was transferred to a long stay ward.

Figure 1: a. Structural axial MRI (fluid-attenuated inversion recovery (FLAIR)): atrophy is within the normal age range. Some white matter hyperintensities in the frontal periventricular regions. b. Structural coronal MRI (T1): atrophy is within the normal age range. c. Results of the [^{18}F]FDG-PET images: A substantial amount of voxels in the frontal, temporal and cingulate cortex were abnormal compared to a healthy reference group. Higher values (red areas) indicate more abnormal voxels and thus more profound metabolic impairment. A: anterior, P: posterior, L: left, R: right.

An attempt lowering the Olanzapine dose did not yield any changes in negative symptoms, but led to increased compulsive behavior. This treatment was therefore maintained. Nearly

15 months later, the patient insisted on discharge to her home, which was permitted with intensive psychiatric and domestic support. There were no signs of psychosis. However, her compulsiveness and apathy remained. A few months later she was found home in a confused state and examined at the emergency ward on the suspicion of dehydration and pneumonia. Shortly after admission on the internal medicine department she suddenly died. Autopsy revealed a fatal thrombus in the pulmonary artery.

Autopsy of the brain was performed and the obtained material was examined independently by AR and WWS. Her brain weighed 1283 grams, without macroscopic atrophy. There was mild arteriolosclerosis without micro-infarction. Nonspecific neurodegenerative changes, such as superficial spongiosis, gliosis, and neuronal loss, were absent. There was a mild amount of diffuse amyloid plaque in the neocortex, extending lightly into entorhinal cortex and CA1/subiculum. Tau-immunoreactive neurofibrillary pathology was mild and limited to locus ceruleus, entorhinal cortex, subiculum, cornu ammonis1, and amygdala, consistent with Braak Stage 2. Immunostains for transactive response DNA Binding Protein-43, alpha-synuclein, and p62 were negative in cortex, basal ganglia, amygdala, substantia nigra, brainstem, pons, locus coeruleus and cerebellum. A post-mortem diagnosis of frontotemporal lobar degeneration or another neurodegenerative disease was excluded. A diagnosis of schizophrenia was established, given the clinical picture combined with the pathological findings.

DISCUSSION

We describe a case with autopsy verified schizophrenia that fulfilled diagnostic criteria for both late-onset schizophrenia and probable bvFTD. We demonstrate that not only symptom overlap with psychiatric disorders may be a pitfall in bvFTD diagnosis, but also that functional decline and abnormal functional neuroimaging findings may occur in psychiatric disorders, therefore questioning the specificity of the bvFTD diagnostic criteria. In this case, psychotic symptoms prevailed initially, leading to a diagnosis of schizophrenia. The patient met the DSM-IV criteria for schizophrenia with delusions, hallucinations and negative symptoms for a period longer than six months. Because compulsive behavior, apathy, and prominent executive dysfunction developed in addition to functional decline, and frontotemporal abnormalities were shown on [18F]FDG-PET, her diagnosis changed to bvFTD according to the FTDC criteria. Because of a decreased CSF amyloid-beta(1-42) level a diagnosis of atypical AD was considered, but regarded unlikely and rejected based on normal CSF tau and phosphorylated tau levels combined with a negative 11C-Pittsburgh compound B-PET scan. Neuropathological examination showed no clinically relevant stage of AD related pathology.

The differentiation between schizophrenia and bvFTD remains a main diagnostic dilemma: for both diagnoses functional decline is required. Although not necessary for diagnosing late-onset schizophrenia, executive abnormalities are often seen upon neuropsychological examination [13]. Furthermore, frontotemporal abnormalities on both structural and functional neuroimaging are common in schizophrenia [14;15]. The overall prevalence of psychosis in bvFTD is about 10%, with relatively higher frequencies in subjects carrying a C9orf72 repeat expansion or progranulin mutation [16]. In this case bvFTD could only be excluded by autopsy.

In the described case, some symptoms cast doubt on the diagnosis of schizophrenia during the course. In contrast to early-onset schizophrenia, the development of negative symptoms and functional decline are uncommon in late-onset schizophrenia, i.e. after the age of 45 years [17]. Moreover, severe compulsiveness is uncommon in schizophrenia [18]. On the other hand, although the absence of empathy is not obligatory for a diagnosis of bvFTD, the relative preservation of empathy in this case is remarkable.

BvFTD symptoms such as apathy, disinhibition and compulsive behavior are seen in other psychiatric disorders such as depression, mania or obsessive-compulsive disorder, but usually do not occur simultaneously in contrast to bvFTD. Apparently due to this symptom overlap, about 50% of bvFTD patients receive a psychiatric diagnosis initially [19]. On the other hand it is currently unknown which proportion of patients with an initial diagnosis of bvFTD turns out to have a psychiatric disorder.

In the FTDC consensus criteria it is stated that the behavioral syndrome should not be better accounted for by a psychiatric condition [4]. This issue is difficult to resolve when the specificity of structural and/or functional neuroimaging appears to be insufficient. Prospective studies addressing this issue among subjects presenting with a late-onset frontal lobe syndrome will hopefully bring answers to this question [20].

REFERENCE LIST

1. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. *Acta Neuropathol* 2009;117:15-8.

2. Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. *Lancet Neurol* 2011;10:162-72.

3. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 1998;51:1546-54.

4. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, ehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134:2456-77.

5. Pose M, Cetkovich M, Gleichgerrcht E, Ibanez A, Torralva T, Manes F. The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood. *Int Rev Psychiatry* 2013;25:159-67.

6. Schroeter ML, Laird AR, Chwiesko C, Deuschl C, Schneider E, Bzdok D, Eickhoff SB, Neumann J. Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia. *Cortex* 2014;57:22-37.

7. Diagnostic and Statistical Manual of Mental Disorders. *American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR).* 2000.

8. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. *Neuroimage* 2002;17:302-16.

9. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, Dekosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol* 2014;13:614-29.

10. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, Van der Flier WM, Ford L, Forster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen

P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Mollergard HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk van Doorn L, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* 2015;313:1924-38.

11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263-9.

12. Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, Kramer JH, van der Vlies AE, Joie RL, Rosen HJ, van der Flier WM, Grinberg LT, Rozemuller AJ, Huang EJ, van Berckel BN, Miller BL, Barkhof F, Jagust WJ, Scheltens P, Seeley WW, Rabinovici GD. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. *Brain* 2015;138:2732-49.

13. Rajji TK, Mulsant BH. Nature and course of cognitive function in late-life schizophrenia: a systematic review. *Schizophr Res* 2008;102:122-40.

14. Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M. Orbitofrontal cortex abnormality and deficit schizophrenia. *Schizophr Res* 2013;143:246-52.

15. Olabi B, Ellison-Wright I, Bullmore E, Lawrie SM. Structural brain changes in First Episode Schizophrenia compared with Fronto-Temporal Lobar Degeneration: a meta-analysis. *BMC Psychiatry* 2012;12:104.

16. Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, Miller BL. Psychosis in Frontotemporal Dementia. *J Alzheimers Dis* 2014.

17. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. *Am J Psychiatry* 2000;157:172-8.

18. Ongur D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. *Schizophr Res* 2005;75:349-62.

19. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. *J Clin Psychiatry* 2011;72:126-33.

20. Krudop WA, Kerssens CJ, Dols A, Prins ND, Moller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Stek ML, Pijnenburg YA. Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. *Am J Geriatr Psychiatry* 2013.